Search Tag: sodium glucose cotransporter 2 inhibition

Cardiology Management

Diabetes Mellitus and Heart Failure

2017 05 Jun

Considering current trial results, patients with diabetes and heart failure may benefit most from glucose-lowering therapies with sodium glucose cotransporter 2 (SGLT2) inhibition, according to a review paper to appear in the American Journal of Cardiology. The beneficial effects of such therapies may be due to "the elimination of glucose via the... Read more